Skip to main content
. Author manuscript; available in PMC: 2024 Mar 1.
Published in final edited form as: Prostaglandins Leukot Essent Fatty Acids. 2023 Jan 26;190:102542. doi: 10.1016/j.plefa.2023.102542

FIGURE 1.

FIGURE 1.

Specialized Pro-resolving Mediators derived from Omega-3 and Eicosanoids from Omega-6 fatty acids [9,10,41]

Specialized pro-resolving mediators are marked in bold font.

Abbreviations: ARA, Arachidonic acid, EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; LTB4, Leukotriene B4; LXA4, Lipoxin A4; LXB4, Lipoxin B4; MaR1–2, Maresin 1–2; PGD2, Prostaglandin D2; PGE2, Prostaglandin E2; PGF2a, Prostaglandin F2 alpha; TXB2, Thromboxane B2; PD1, Protectin D1; RA, rheumatoid arthritis; RvD1, RvD2, RvD3, RvD4, RvD5, and RvD6, D-series resolvins; RvE1, RvE2, RvE3, and RvE4, E-series resolvins; 14-HDHA, 14-hydroxy-docosahexaenoic acid; 15-HEPE, 15-hydroxyeicosapentaenoic acid; 17-HDHA, 17-hydroxy-docosahexaenoic acid; 18-HEPE, 18-hydroxyeicosapentaenoic acid.